Efficacy of bevacizumab for posttraumatic choroidal neovascularization

Acta Ophthalmol. 2019 Mar;97(2):e324-e326. doi: 10.1111/aos.13896. Epub 2018 Nov 9.

Authors

Kwangsic Joo¹, Taewoong Um², Sang Jun Park¹, Joon Hee Cho^{1

3}, Jeeyun Ahn⁴, Jee Taek Kim⁵, Joo Yong Lee², Kyu Hyung Park¹, Se Joon Woo¹

Affiliations

¹ Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
² Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
³ Hyemin Eye Hospital, Seoul, Korea.
⁴ Department of Ophthalmology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
⁵ Department of Ophthalmology, Chung-Ang University College of Medicine, Seoul, Korea.

PMID: 30414255
DOI: 10.1111/aos.13896

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Aged
Angiogenesis Inhibitors / therapeutic use*
Bevacizumab / therapeutic use*
Child
Choroid / injuries*
Choroidal Neovascularization / drug therapy*
Choroidal Neovascularization / etiology
Choroidal Neovascularization / physiopathology
Eye Injuries / drug therapy*
Eye Injuries / etiology
Eye Injuries / physiopathology
Female
Humans
Intravitreal Injections
Male
Middle Aged
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Young Adult

Substances

Angiogenesis Inhibitors
VEGFA protein, human
Vascular Endothelial Growth Factor A
Bevacizumab